roxadustat

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Hemodialysis Chronic Kidney Disease Patients With Anemia

Drug Information

Target Indication

Hemodialysis Chronic Kidney Disease Patients With Anemia

Clinical Trial

Last updated: 12/23/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMA8/18/2021

Evrenzo

Evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD).

Drug Science

Mechanism of action & safety profile

Developer

ALPMY

Astellas Pharma

Related Pipeline

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer

Clostridium Difficile-associated Diarrhea (CDAD)

Psoriatic Arthritis

Anemia

Heart Transplantation